Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.OctoPlus to perform process development and clinical manufacturing of Axentis' lead product
Subscribe to our email newsletter
OctoPlus has signed a pharmaceutical development and manufacturing contract with Axentis Pharma. The undisclosed contract value contributes to OctoPlus’ annual revenues, for which the company reiterates its guidance of E19m.
Under the terms of the deal, OctoPlus will perform process development and clinical manufacturing of Axentis Pharma’s lead product, which is an inhalable liposomal formulation of tobramycin for the treatment of cystic fibrosis.
OctoPlus provides formulation development and clinical material manufacturing services to biotech and pharmaceutical companies. The company offers its clients drug delivery technologies for the development of controlled release versions of existing or new drugs.
Axentis Pharma is a respiratory specialty pharmaceutical company whose core competence is the combination of a liposome-based drug delivery system with therapeutic agents. The company is using its platform delivery technology, named Fluidosomes technology, for the development of its lead product, an inhalable liposomal formulation of tobramycin.